SI2744831T1 - Transferin-tumstatin fuzijski protein in metode za izdelavo in uporabo le-tega - Google Patents
Transferin-tumstatin fuzijski protein in metode za izdelavo in uporabo le-tega Download PDFInfo
- Publication number
- SI2744831T1 SI2744831T1 SI201231232T SI201231232T SI2744831T1 SI 2744831 T1 SI2744831 T1 SI 2744831T1 SI 201231232 T SI201231232 T SI 201231232T SI 201231232 T SI201231232 T SI 201231232T SI 2744831 T1 SI2744831 T1 SI 2744831T1
- Authority
- SI
- Slovenia
- Prior art keywords
- tumstatin
- recombinant protein
- nucleic acid
- recombinant
- transferrin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 7
- 108020001507 fusion proteins Proteins 0.000 title claims 2
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract 16
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract 16
- 102100033780 Collagen alpha-3(IV) chain Human genes 0.000 claims abstract 12
- 108010012374 type IV collagen alpha3 chain Proteins 0.000 claims abstract 12
- 102000004338 Transferrin Human genes 0.000 claims abstract 8
- 108090000901 Transferrin Proteins 0.000 claims abstract 8
- 239000012581 transferrin Substances 0.000 claims abstract 8
- 239000013612 plasmid Substances 0.000 claims abstract 3
- 102000004169 proteins and genes Human genes 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract 2
- 150000007523 nucleic acids Chemical group 0.000 claims 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 claims 1
- 208000005598 Angioid Streaks Diseases 0.000 claims 1
- 208000033825 Chorioretinal atrophy Diseases 0.000 claims 1
- 201000002563 Histoplasmosis Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 201000004613 Pseudoxanthoma elasticum Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000023558 pseudoxanthoma elasticum (inherited or acquired) Diseases 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (12)
- TRANSFERIN-TUMSTATIN FUZIJSKI PROTEIN IN METODE ZA IZDELAVO IN UPORABO LE-TEGA PATENTNI ZAHTEVKI1. Rekombinantni protein, ki obsega transferin, ki je povezan s tumstatinom.
- 2. Rekombinantni protein po zahtevku 1, pri čemer sta transferin in tumstatin direktno vezana drug na drugega.
- 3. Rekombinantni protein po zahtevku 1, kjer sta transferin in tumstatin kovalentno povezana med seboj z linkerjem.
- 4. Plazmid, ki obsega sekvenco nukleinske kisline, ki kodira rekombinantni protein, ki obsega transferin, ki je povezan s tumstatinom kot po zahtevku 1.
- 5. Plazmid po zahtevku 4, kjer je sekvenca nukleinske kisline, ki kodira rekombinantni protein, operativno vezana na ekspresijsko kontrolno sekvenco.
- 6. Rekombinantna molekula nukleinske kisline, ki obsega sekvenco nukleinske kisline, ki kodira rekombinantni protein, ki obsega: transferin, ki je povezan s tumstatinom po zahtevku 1.
- 7. Molekula rekombinantne nukleinske kisline po zahtevku 6, kjer je sekvenca nukleinske kisline operativno vezana na ekspresijsko kontrolno sekvenco.
- 8. Rekombinantna gostiteljska celica, ki je transficirana z in izraža rekombinantno molekulo nukleinske kisline, obsega sekvenco nukleinske kisline, ki kodira rekombinantni protein, ki obsega transferin, ki je vezan na tumstatin kot je navedeno v zahtevku 6.
- 9. Postopek za pripravo rekombinantnega proteina, ki obsega transferin, ki je povezan s tumstatinom, kot je zahtevano v zahtevku 1, pri čemer omenjeni postopek obsega: transfekcijo rekombinantne gostiteljske celice z molekulo rekombinantne nukleinske kisline, ki obsega sekvenco nukleinske kisline, ki kodira rekombinantni protein, ki obsega transferin, ki je povezan s tumstatinom po zahtevku 6; kultiviranje transficirane gostiteljske celice v pogojih, ki zadoščajo za produkcijo rekombinantnega proteina, ki obsega transferin, ki je povezan s tumstatinom; in rekuperiranje rekombinantnega proteina kot v bistvu očiščenega rekombinantnega proteina
- 10. Postopek po zahtevku 9, kjer rekombinantni protein obsega transferin, ki je neposredno povezan s tumstatinom kot po zahtevku 2.
- 11. Rekombinantni protein, ki obsega transferin, ki je povezan s tumstatinom, kot je definiran v zahtevku 1, za uporabo pri zdravljenju kliničnega stanja, povezanega s horoidalno neovaskularizacijo (CNV).
- 12.Rekombinantni protein, kot je definiran v zahtevku 1, za uporabo, kot je definirano v zahtevku 11, kjer klinično stanje povezano s CNV, obsega pseudoxanthoma elasticum, angioidne črte (ang.«angioid streaks«), histoplazmozo, punktantna notranja horoidopatija ali s starostjo povezana mokra makularna degeneracija.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161524508P | 2011-08-17 | 2011-08-17 | |
| EP12824616.2A EP2744831B1 (en) | 2011-08-17 | 2012-08-15 | Transferrin-tumstatin fusion protein and methods for producing and using the same |
| PCT/US2012/051013 WO2013025846A2 (en) | 2011-08-17 | 2012-08-15 | Transferrin-tumstatin fusion protein and methods for producing and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2744831T1 true SI2744831T1 (sl) | 2018-04-30 |
Family
ID=47715692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201231232T SI2744831T1 (sl) | 2011-08-17 | 2012-08-15 | Transferin-tumstatin fuzijski protein in metode za izdelavo in uporabo le-tega |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9290562B2 (sl) |
| EP (1) | EP2744831B1 (sl) |
| JP (1) | JP6073888B2 (sl) |
| CN (2) | CN103998470A (sl) |
| AU (1) | AU2012296588B2 (sl) |
| BR (1) | BR112014008680A2 (sl) |
| CA (1) | CA2849015C (sl) |
| DK (1) | DK2744831T3 (sl) |
| ES (1) | ES2659161T3 (sl) |
| NO (1) | NO2820418T3 (sl) |
| PL (1) | PL2744831T3 (sl) |
| PT (1) | PT2744831T (sl) |
| SI (1) | SI2744831T1 (sl) |
| TR (1) | TR201802686T4 (sl) |
| WO (1) | WO2013025846A2 (sl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016520053A (ja) * | 2013-05-06 | 2016-07-11 | 中国▲薬▼科大学Ｃｈｉｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ | 腫瘍微小環境における血管再生の抑制及び適応免疫応答の活性化を有する二機能の融合タンパク質及びその遺伝子並びに使用 |
| WO2014203182A1 (en) * | 2013-06-20 | 2014-12-24 | Novartis Ag | Use of a vegf antagonist in treating choroidal neovascularisation |
| US11058750B2 (en) * | 2015-12-03 | 2021-07-13 | Mor Research Applications Ltd. | Compositions and methods for treatment of ocular diseases |
| KR101818151B1 (ko) | 2016-03-25 | 2018-01-16 | 한국과학기술원 | 트렌스페린을 포함하는 허혈성망막병증 예방 및 치료용 조성물 |
| CN109053899B (zh) * | 2017-12-22 | 2021-11-16 | 湖南远泰生物技术有限公司 | 一种含人转铁蛋白抗原表位序列的嵌合体抗原受体 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672683A (en) | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| US20050192242A1 (en) | 1995-10-11 | 2005-09-01 | Neal Zane C. | Therapeutic fusion protein transgenes |
| CN1309663A (zh) * | 1998-06-17 | 2001-08-22 | 贝斯以色列护理医疗中心 | 抗血管生成蛋白及其应用 |
| JP2003517847A (ja) | 1999-12-23 | 2003-06-03 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | トランスフェリンポリヌクレオチド、ポリペプチド、および抗体 |
| US8129504B2 (en) * | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
| US20040023334A1 (en) | 2001-08-30 | 2004-02-05 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
| EP1463751B1 (en) | 2001-12-21 | 2013-05-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1471928A1 (en) * | 2002-02-07 | 2004-11-03 | Delta Biotechnology Limited | Hiv inhibiting proteins |
| US8188032B2 (en) | 2003-10-10 | 2012-05-29 | National Institutes Of Health (Nih) | G-CSF transferrin fusion proteins |
| EP1722762A2 (en) * | 2004-03-02 | 2006-11-22 | Massachusetts Institute of Technology | Nanocell drug delivery system |
| EP1812030A4 (en) * | 2004-10-14 | 2009-01-14 | Sopherion Therapeutics Inc | ANTI-ANGIOGENIC PEPTIDES AND METHODS OF USE THEREOF |
| WO2006049983A2 (en) | 2004-10-27 | 2006-05-11 | Biorexis Pharmaceutical Corporation | Peptide yy modified transferrin fusion proteins |
| CA2606989A1 (en) * | 2005-04-29 | 2006-11-09 | Research Development Foundation | Vascular targeting of ocular neovascularization |
| US8227419B2 (en) | 2006-02-03 | 2012-07-24 | Crc For Asthma And Airways Ltd. | Method of treating conditions associated with airway tissue remodeling |
| CN101070349B (zh) * | 2007-05-22 | 2010-10-13 | 山西康宝生物制品股份有限公司 | 具有选择性杀伤肿瘤新生血管内皮细胞作用的融合蛋白与应用 |
| CN101092452A (zh) * | 2007-05-23 | 2007-12-26 | 哈尔滨医科大学 | 肿瘤抑素抗血管生成小分子多肽、融合蛋白及两者制备方法 |
| US7943733B2 (en) * | 2007-12-20 | 2011-05-17 | University Of Southern California | Spacers to increase the expression of recombinant fusion proteins |
| ES2676878T3 (es) | 2011-03-03 | 2018-07-25 | Zymeworks Inc. | Diseño de armazón de heteromultímero multivalente y constructos |
-
2012
- 2012-08-15 SI SI201231232T patent/SI2744831T1/sl unknown
- 2012-08-15 CN CN201280051256.4A patent/CN103998470A/zh active Pending
- 2012-08-15 PT PT128246162T patent/PT2744831T/pt unknown
- 2012-08-15 DK DK12824616.2T patent/DK2744831T3/en active
- 2012-08-15 TR TR2018/02686T patent/TR201802686T4/tr unknown
- 2012-08-15 CA CA2849015A patent/CA2849015C/en active Active
- 2012-08-15 US US14/239,176 patent/US9290562B2/en active Active
- 2012-08-15 JP JP2014526189A patent/JP6073888B2/ja active Active
- 2012-08-15 BR BR112014008680A patent/BR112014008680A2/pt unknown
- 2012-08-15 WO PCT/US2012/051013 patent/WO2013025846A2/en active Application Filing
- 2012-08-15 CN CN201910156923.9A patent/CN110105453A/zh active Pending
- 2012-08-15 ES ES12824616.2T patent/ES2659161T3/es active Active
- 2012-08-15 PL PL12824616T patent/PL2744831T3/pl unknown
- 2012-08-15 AU AU2012296588A patent/AU2012296588B2/en active Active
- 2012-08-15 EP EP12824616.2A patent/EP2744831B1/en active Active
-
2013
- 2013-07-22 NO NO13745268A patent/NO2820418T3/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2659161T3 (es) | 2018-03-14 |
| AU2012296588B2 (en) | 2017-07-27 |
| AU2012296588A1 (en) | 2014-04-03 |
| JP6073888B2 (ja) | 2017-02-01 |
| BR112014008680A2 (pt) | 2017-06-13 |
| DK2744831T3 (en) | 2018-03-05 |
| TR201802686T4 (tr) | 2018-03-21 |
| PT2744831T (pt) | 2018-03-05 |
| WO2013025846A3 (en) | 2013-05-02 |
| CN110105453A (zh) | 2019-08-09 |
| JP2014526890A (ja) | 2014-10-09 |
| US20140179612A1 (en) | 2014-06-26 |
| EP2744831B1 (en) | 2017-12-06 |
| US9290562B2 (en) | 2016-03-22 |
| CA2849015C (en) | 2017-08-08 |
| CA2849015A1 (en) | 2013-02-21 |
| EP2744831A4 (en) | 2015-03-11 |
| EP2744831A2 (en) | 2014-06-25 |
| PL2744831T3 (pl) | 2018-05-30 |
| CN103998470A (zh) | 2014-08-20 |
| WO2013025846A2 (en) | 2013-02-21 |
| NO2820418T3 (sl) | 2018-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201815T1 (hr) | Nukleinske kiseline za liječenje alergija | |
| HRP20191409T1 (hr) | Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula | |
| SI2744831T1 (sl) | Transferin-tumstatin fuzijski protein in metode za izdelavo in uporabo le-tega | |
| AR124240A2 (es) | Un anticuerpo biespecífico anti-vegf / anti-ang-2, ácido nucleico, vector de expresión, célula huésped y un método de preparación del anticuerpo | |
| FI3835310T3 (fi) | Fibronektiinipohjaisia telinedomeeniproteiineja, jotka sitoutuvat myostatiiniin | |
| BR112013020338A2 (pt) | proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira | |
| HRP20221447T1 (hr) | Fuzijski proteini koji sadrže dijelove za vezanje pdgf i vegf i postupci njihove upotrebe | |
| JP2012522529A5 (sl) | ||
| BR112014008694A2 (pt) | moléculas de ácido nucleico policistrônico recombinante | |
| ES2732907T3 (es) | Procedimiento de expresión | |
| BR112012007294A2 (pt) | moléculas de ligação a dll4 | |
| HRP20211594T1 (hr) | Anti-pd1 protutijela i načini uporabe | |
| AR094141A1 (es) | Composiciones y metodos para proteinas de accion prolongada | |
| JP2013135695A5 (sl) | ||
| BR112012008142A2 (pt) | conjugados de peptídeo/ polietilenoglicol liga dos a dissulfeto para a transfecção de ácidos nucleicos | |
| PE20170071A1 (es) | Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas | |
| HRP20190472T4 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| WO2013120012A3 (en) | Cdim binding proteins and uses thereof | |
| BR112015014751A8 (pt) | anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos. | |
| MY162564A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| BR112015019879A2 (pt) | Composições de espécies de variantes moduladas de lisina e métodos para produção e uso das mesmas | |
| SI2542257T1 (sl) | Optimizirna monoklonska protitelesa proti inhibitorju poti tkivnega faktorja (TFPI) | |
| BRPI1008145B8 (pt) | Proteína de ligação de antígeno biespecífica, método para preparar uma proteína de ligação de antígeno biespecífica, micro-organismo transgênico, composição farmacêutica e uso da proteína de ligação de antígeno biespecífica | |
| MY171007A (en) | Bispecific binding molecules binding to vegf and ang2 | |
| MX2014007516A (es) | Procesos que utilizan vlps con capsides resistentes a hidrolasas. |